News for DMTK Stock

DermTech Files for Voluntary Chapter 11 Protection DermTech Reports First-Quarter 2024 Financial Results DermTech to Explore Strategic Alternatives and Implement Restructuring Plan DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) DermTech Presents Research Abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting and New Research Published in the Journal of Investigative Dermatology DermTech Reports Fourth-Quarter 2023 Financial Results DermTech Announces Release Date for Fourth-quarter 2023 Financial Results DermTech Announces Additional Restructuring Actions to Focus on Revenue Growth and Streamline Operations DermTech Announces Positive Topline Results From a Study Evaluating the DermTech Melanoma Test (DMT) Across All Skin Types DermTech Simplifies the DermTech Melanoma Test (DMT) by Discontinuing the Optional TERT Add-on Assay DermTech Announces Positive Topline Results From Trust 2 Study Evaluating the DermTech Melanoma Test (DMT) DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) DermTech Reports Third-Quarter 2023 Financial Results DermTech Announces Release Date for Third-Quarter 2023 Financial Results DermTech Grants New CCO Mark Aguillard Inducement Award Under NASDAQ Listing Rule 5635(c)(4) DermTech Announces Contracts With Highmark for the Foundational Assay of Its DermTech Melanoma Test (DMT) DermTech Appoints Mark Aguillard as Chief Commercial Officer DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) DermTech Reports Second-Quarter 2023 Financial Results DermTech Announces Favorable Coverage Policy With Blues Plan in Michigan for the Foundational Assay of Its DermTech Melanoma Test (DMT) DermTech Announces Release Date for Second-Quarter 2023 Financial Results DermTech Adds Approximately 7 Million Covered Lives for the Foundational Assay of Its DermTech Melanoma Test (DMT) DermTech Announces Restructuring to Prioritize Growth Opportunities and Streamline Operations ECRI Completes Evaluation of the Pigmented Lesion Assay (PLA), the Foundational Assay for the DermTech Melanoma Test (DMT) DermTech Announces Contract With Hawaii Blues Plan for the Foundational Assay of Its DermTech Melanoma Test (DMT) DermTech Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) DermTech Surpasses 200,000 Cumulative Billable Samples for the DermTech Melanoma Test (DMT) DermTech Announces Agreements With South Carolina Blues Plan and the United Mine Workers of America Health and Retirement Funds for the Foundational Assay of Its DermTech Melanoma Test (DMT) DermTech Grants New CEO Bret Christensen Inducement Award Under NASDAQ Listing Rule 5635(c)(4) DermTech Appoints Bret Christensen as New President and CEO DermTech Reports First-Quarter 2023 Financial Results New Survey Data Reveals Nearly 75% of Consumers Have Not Had a Full Skin Exam Within the Past 12 Months DermTech Announces Contract With New York Health Plan for the Foundational Assay of Its DermTech Melanoma Test (DMT) DermTech Announces Release Date for First-quarter 2023 Financial Results DermTech Announces Contract With North Carolina Blues Plan for the Foundational Assay of Its DermTech Melanoma Test (DMT) New Survey Finds Millennials and Gen Xers Not Following Safe Sun Habits, Increasing Risk of Nonmelanoma Skin Cancer DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) DermTech to Present Four New Posters and Demonstrate its Smart Stickers™ at the 2023 American Academy of Dermatology (AAD) Annual Meeting DermTech Adds Approximately 1.9 Million Covered Lives for the Foundational Assay of Its DermTech Melanoma Test (DMT) DermTech to Present at March Investor Conferences DermTech Reports Fourth-Quarter and Full-Year 2022 Financial Results; Company Announces CEO Transition Plan DermTech Announces Release Date for Fourth-Quarter 2022 Financial Results DermTech Announces the Foundational Assay of Its DermTech Melanoma Test (DMT) Is Recommended for Coverage by the Veterans Health Administration DermTech Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) DermTech Adds Approximately 1.2 Million Covered Lives for the Foundational Assay of Its DermTech Melanoma Test (DMT) DermTech Announces the Foundational Assay of Its DermTech Melanoma Test (DMT) Is Recommended for Coverage by TRICARE DermTech Adds Approximately 13 Million Covered Lives for the Foundational Assay of Its DermTech Melanoma Test (DMT) DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) DermTech and Sonora Quest Laboratories Expand Access to Innovative Melanoma Detection Test DermTech Reports Third-Quarter 2022 Financial Results DermTech Announces Release Date for Third-Quarter 2022 Financial Results DermTech Presents on Translational Medicine to Revolutionize Dermatologic Care at the Biomarkers & Precision Medicine USA Congress DermTech Presents on Technological Advances and the Value of Decentralization at Outsourcing in Clinical Trials Southern California DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) DermTech Reports Second-Quarter 2022 Financial Results; Company Updates Full-Year 2022 Outlook DermTech Appoints Chief Compliance Officer and SVP of Research and Development DermTech Announces Release Date for Second-Quarter 2022 Financial Results DermTech Appoints Two New Board Members DermTech Joins PeDRA Corporate Council, Supporting Efforts to Address Pediatric Skin Diseases DermTech to Present on Genomic Innovation in Dermatology at AHIP 2022 DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) DermTech to Present at the William Blair Growth Stock Conference DermTech Sponsors The Sun Bus to Bring Free Skin Cancer Screenings to More Than 50 Locations Across the U.S. DermTech Presents New Research Differentiating Atopic Dermatitis and Psoriasis at the Society for Investigative Dermatology’s Annual Meeting DermTech Reinforces Longstanding Mission to Help Reduce Melanoma Deaths, Aligning with the Biden Administration’s Renewed ‘Cancer Moonshot’ Program DermTech Kicks Off Second Annual #Stickit2Melanoma Campaign, Raising Awareness for Melanoma and the Importance of Skin Exams DermTech Reports First-Quarter 2022 Financial Results; Company Affirms Full-Year 2022 Outlook DermTech Announces Publication of New GvHD Clinical Research Conducted in Collaboration with Memorial Sloan Kettering Cancer Center DermTech Expands Telehealth Application, DermTech Connect, Across 44 States DermTech to Showcase DermTech Stratum, an Expanded Translational Medicine Service Offering, at San Diego’s Inaugural ‘Innovation Day’ Event DermTech Announces Release Date for First-Quarter 2022 Financial Results CasperLabs Appoints Michael Dobak as Company’s First Chief Marketing Officer to Drive Business Adoption of Blockchain Technology DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) DermTech Study, “Cost-Benefit Analysis of the Pigmented Lesion Assay When Introduced into the Visual Assessment / Histopathology Pathway for Lesions Clinically Suspicious for Melanoma,” Published in SKIN: The Journal of Cutaneous Medicine DermTech Reports Fourth Quarter and Full Year 2021 Financial Results DermTech Management to Present at Upcoming Investor Conferences DermTech Welcomes Adelle Walker as Vice President of Consumer Products DermTech to Announce Fourth Quarter and Full-Year Financial Results DermTech Management to Participate in Upcoming Investor Conferences BioIQ and DermTech Enter into an Agreement to Add Non-invasive DermTech Melanoma Test to BioIQ's Health Testing Solution Lineup DermTech Unveils DermTech Stratum, an Expanded Translational Medicine Service Offering for Non-invasive Biomarker Analysis DermTech Presents Precision Approaches to Personalized Dermatology at 2021 Dermatology Drug Development Summit DermTech Reports Third Quarter 2021 Financial Results DermTech and DermatologistOnCall Enter Agreement to Improve Access to the DermTech Melanoma Test with Noninvasive, At-Home Sample Collection DermTech Management to Participate in Upcoming Investor Conferences DermTech to Announce Third Quarter Financial Results on November 9, 2021 DermTech Presents in Expert Panel at Inaugural Alliance for Innovation in Integrated Healthcare Summit DermTech Announces New Appointment of L’Oréal USA Leader Nathalie Gerschtein Keraudy to its Board of Directors DermTech Sponsors San Diego Open; Partners with Tennis Pro Brandon Nakashima to Raise Awareness for Sun Safety DermTech Study, “Non-Invasive Detection of Genomic Atypia Increases Real-World NPV and PPV of the Melanoma Diagnostic Pathway and Reduces Biopsy Burden,” Published in SKIN: The Journal Of Cutaneous Medicine DermTech Management to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit DermTech to Present at Florida Association of Health Plans 2021 Annual Conference DermTech Management to Participate at the Lake Street 2021 BIG5 Conference DermTech Reports Second Quarter 2021 Financial Results DermTech to Announce Second Quarter Financial Results on August 4, 2021 DermTech Announces New San Diego Headquarters DermTech Announces New Appointment of Monica Tellado to its Board of Directors DermTech CEO John Dobak, M.D. Wins San Diego Business Journal CEO of the Year Award, Public Company, Medium Category DermTech to Partner with University of Barcelona for Research Study on Atopic Dermatitis and Psoriasis DermTech Announces Three New Key Leadership Appointments: Chief Medical Officer, Vice President, Sales and Vice President, Information Technology and Digital Systems DermTech Announces Three New Scientific Advisory Board Members DermTech Management to Participate in Upcoming Investor Conferences DermTech Reports First Quarter 2021 Financial Results DermTech Management to Present at the UBS Global Healthcare Virtual Conference DermTech Presents Mini-Symposia at 2021 Society of Investigational Dermatology Virtual Summit DermTech Pledges up to $1 Million to Raise Awareness and Support Accessibility of Skin Exams DermTech to Announce First Quarter Financial Results on May 13, 2021 DermTech to Collaborate on Longitudinal Study on Hidradenitis Suppurativa (HS) DermTech Introduces PLAplus with Improved Sensitivity for Early Detection of Melanoma DermTech Joins Skin Cancer Foundation Corporate Council OptumInsight Study Describes Cost Savings of DermTech’s Pigmented Lesion Assay in the Management of Melanoma DermTech Reports Fourth Quarter and Full Year 2020 Financial Results DermTech Abstracts Selected to Present at Society of Investigative Dermatology Virtual Meeting DermTech to Announce Fourth Quarter 2020 Financial Results on March 4, 2021 DermTech Management to Participate in Upcoming Investor Conferences DermTech Enters Into Agreement with Blue Cross Blue Shield of Texas DermTech Announces New Scientific Advisory Board Members DermTech Management to Present at the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference DermTech Featured in Melanoma Research Foundation Weekly “Ask the Expert” Facebook Live Events Alongside Notable Industry Scientists DermTech Chief Scientific Officer Michael Howell Presented at Dermatology Summit 2021 DermTech Pigmented Lesion Assay (PLA) to Enrich Melanoma Positivity Nearly Five-Fold in Biopsied Lesions: Findings from a Large US Registry DermTech Announces Inclusion of Non-Invasive Genomic Patch Testing in the National Comprehensive Cancer Network® (NCCN) Cutaneous Melanoma Guidelines DermTech Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares DermTech Announces Pricing of Public Offering of Common Stock DermTech Announces Proposed Public Offering of Common Stock DermTech Announces Appointment of General Counsel DermTech Receives Positive Medical Coverage by Geisinger Health System DermTech Management to Present at the ICR Conference 2021 DermTech Announces Topline Results of its TRUST Study: Results Confirm the High Negative Predictive Value of the PLA at 99% and Find No Significant Adverse Outcomes After Long-Term Follow-Up of PLA Negative Tests DermTech’s Melanoma Test Included in Two Continuing Medical Education (“CME”) Sessions at 2020 Fall Clinical Virtual Grand Rounds and Mount Sinai Winter Symposium DermTech Enters Into Agreement With Blue Shield of California DermTech Presents Updates in Precision Medicine at 2020 Dermatology Drug Development Summit DermTech Enters Agreement with Blue Cross Blue Shield of Illinois DermTech Presents New Clinical Research Abstract at the 2020 Fall Clinical Dermatology Conference DermTech Reports Third Quarter 2020 Financial Results DermTech to Participate in Upcoming Investor Conferences DermTech to Announce Third Quarter 2020 Financial Results on November 10, 2020